Cassandra Pardini

The patient, who presented to the clinical office complaining of dysuria, was diagnosed with a urinary tract infection and was prescribed TMP-SMX.

Study authors aimed to assess the clinical impact of a POC PCR test (the Cobas LIAT Influenza A/B assay) for the diagnosis of influenza.

Due to the limited amount of published literature analyzing treatment options for older chronic HCV infection patients, the study authors aimed to determine the efficacy and tolerability of glecaprevir/pibrentasvir in this population.

The patient, who had a history significant for cerebral palsy, seizures, and chronic constipation, presented complaining of 3 days of fever, nausea, vomiting, and anorexia.

The trial analyzed the antibody response of 103 asthmatic patients to the seasonal influenza vaccine.

The study included 17,149,480 patients obtained from 2 national laboratory datasets who were screened between 2013 and 2016 based on an AB test.

In order to determine HCV reinfection rates following sustained virologic response (SVR) in the overall population as well as in PWID, the study authors analyzed data obtained from a population-based study that included >1.7 million people that were tested for HCV.

ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) was utilized to identify all patients who received HCV treatment for at least 7 weeks as well as a propensity-score matched group who did not receive treatment.

In order to determine the association between CHC and parkinsonism, the study authors utilized the National Health Insurance Research Database in Taiwan to identify CHC patients between 2004 and 2012.

The retrospective study aimed to determine the risk of incident, or de novo, HCC following different regimens of antiviral therapy.

The review analyzed 168 patients treated with an oral DAA at a single center from 2015 to 2017.

The study utilized data from the Chronic Hepatitis Cohort Study, an observational cohort study, to assess demographic and clinical characteristics associated with DAA use.

The study compared US administrative claims data of HCV patients with ≥12 weeks of dispensed DAA therapy (N=17,848) to untreated HCV patients with follow-up data (N=108,350).

The study aimed to determine whether direct-acting antiviral therapy reduced fibrosis and assessed whether any predictors of treatment failure existed at 1-year follow-up.

The aim of the study was to assess both treatment evaluation and treatment initiation rates from various practice settings between January 2002 and December 2016.

A recent report published in the Journal of Pharmacy Practice describes the case of a 75-year-old female patient who developed acquired hemophilia following levofloxacin administration.

Vancomycin administered via continuous infusion was found to achieve the recommended VAN trough of 15-20mg/L faster and with less risk of adverse events compared to administration via intermittent infusion.

Repeated intravenous administration of penicillin antibiotics appears to be safe in patients with a reported penicillin allergy and a negative penicillin allergy test.

The combination of tenofovir disoproxil fumarate, emtricitabine, and efavirenz was associated with the lowest risk of adverse birth outcome compared to other ART treatments.